Disclosed is the use of: a) an effective amount of at least one specific binding molecule, or fragment thereof, wherein the specific binding molecules are polyclonal immunoglobulin Y (IgY) antibodies prepared in eggs of hens inoculated with one or a mixture of pathogenic components, wherein the (IgY) antibodies comprise a mixture of IgY specific for antigens derived from Escherichia coli, rotavirus, and coronavirus pathogens, pathogen related toxins, and/or pathogen related adhesion elements； and, b) a carrier matrix comprising a matrix obtained from, isolated from, or derived from, bovine colostrum, and that comprises at least two components obtained from a nonhuman animal selected from the group consisting of enzymes, lactoferrin, transferrin, nonspecific immunoglobulins, cytokines, white blood cells, complement components, interferons, and fibronectin in the manufacture of a medicament for treating diarrhea, wherein the mixture of IgY antibodies is in an effective amount for the treatment or prevention of undifferentiated diarrhea, traveler&rsquo；s diarrhea, rotavirus diarrhea, toxin-mediated diarrhea, cholera, C. difficile infection, dysentery, typhoid fever, peptic ulcers, or for gastrointestinal flora management in a non-neonate human.
